A randomised, double-blind, placebo-controlled trial of trichuris suis ova in active crohn's disease
Jürgen Schölmerich(University of Hohenheim), International TRUST-2 Study Group, Andreas Munk Petersen(University of Copenhagen), Klaus Fellermann(Apple (Israel)), Jost Langhorst(ThyssenKrupp (Germany)), Gottfried Novacek(Medical University of Vienna), Norbert Hesselbarth(Klinikum Ingolstadt), Niels Teich(Leipzig University), Jan Wehkamp(Robert Bosch Hospital), Ralph Müeller(Dr Falk Pharma (Germany)), Claudia Ott(University Hospital Regensburg), Karin Dilger(Dr Falk Pharma (Germany)), Jochen Klaus(University Hospital Ulm), Harald Matthes, Stefanie Howaldt, Oliver Bachmann, Gerhard Rogler, Roland Greinwald(Dr Falk Pharma (Germany)), Frank Seibold(Lindenhofspital)
Open MIND
January 1, 2017
Cited by 16
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
Origins of the <i>E. coli</i> Strain Causing an Outbreak of Hemolytic–Uremic Syndrome in Germany
|New England Journal of Medicine|2011|833
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566